Trial · NCT01652690
Registered outcomes14
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 14 of 14
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants Receiving All Prescriptions and Injections of Denosumab From the Initial Prescribing Physician's Office | 24 months | Number of participants who received all injection(s), including baseline injection, from the initial prescribing site irrespective of total number of injections received on study. |
| Primary | Number of Participants Receiving an Individual Prescription and Injection of Denosumab From the Initial Prescribing Physician Office by Each Individual Injection | Baseline (day 1), and at Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively) | |
| Primary | Number of Participants Receiving All Prescriptions and Injections of Denosumab | Months 6, 12, 18 and 24 (corresponding to the first, second, third and fourth post-baseline injections respectively) | Number of participants receiving all prescriptions and injections of denosumab whether or not the injections are given at the initial prescribing physician's office. |
| Primary | Number of Participants With a Referral by the Prescribing Physician to Other Health Care Providers for Continuation or Follow-up of Care | 24 months | |
| Primary | Types of Health Care Providers Administering an Individual Injection of Denosumab at the Baseline Injection | Baseline (day 1) | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the baseline injection. |
| Primary | Types of Health Care Providers Administering Denosumab at the First Post-baseline Injection | Month 6 | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the first post-baseline injection. |
| Primary | Types of Health Care Providers Administering Denosumab at the Second Post-baseline Injection | Month 12 | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the second post-baseline injection. |
| Primary | Types of Health Care Providers Administering Denosumab at the Third Post-baseline Injection | Month 18 | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the third post-baseline injection. |
| Primary | Types of Health Care Providers Administering Denosumab at the Fourth Post-baseline Injection | Month 24 | Types of health care providers administering an individual injection of denosumab inside or outside the initial prescribing office at the fourth post-baseline injection. |
| Primary | Number of Denosumab Post-baseline Injections Received by Each Participant | 24 months | |
| Primary | Number of Participants Having Radiologic Bone Assessments | Pre-baseline (before first denosumab injection) and during the study (post-baseline) | Number of participants having radiologic bone assessments pre-treatment with denosumab and during the study. |
| Primary | Number of Participants Having Osteoporosis Related Laboratory Examinations | Pre-baseline (before first denosumab injection) and post-baseline | Number of participants having osteoporosis related laboratory examinations pre-treatment with denosumab and during the study. Participants may not have been given denosumab injection when they attended each visit. |
| Secondary | Number of Participants With Adverse Drug Reactions (ADRs) to Denosumab | 24 months | Adverse events (AEs) that were considered related to denosumab as evaluated by the investigator were classified as adverse drug reactions (ADRs). |
| Secondary | Number of Participants With Serious ADRs to Denosumab | 24 months | Serious adverse events that were considered related to denosumab were classified as serious adverse drug reactions (SADRs). A serious adverse event (SAE) is any AE that also: • is fatal • is life threatening (places the patient at immediate risk of death) • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • is an "other significant medical hazard" that does not meet any of the above criteria. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT01652690/registered